[Joint disease in inflammatory bowel disease]
- PMID: 15811268
- DOI: 10.1157/13073095
[Joint disease in inflammatory bowel disease]
Abstract
The joint disorders taxonomically included in the group of seronegative spondyloarthropathies under the generic name of enteropathic arthropathy represent the most frequent extra-intestinal manifestation of inflammatory bowel disease (IBD), affecting 33% of patients. Their frequency is similar to that of ulcerative colitis and Crohn's disease. Enteropathic arthropathy consists of two main joint alterations, peripheral and axial arthritis, as well as a variable group of other peri-articular disorders. Type 1, or pauciarticular, peripheral arthritis generally coincides with IBD exacerbations, while type 2, or polyarticular, peripheral arthritis follows an independent course from IBD. Axial involvement precedes and follows an independent course from IBD and can behave as ankylosing spondylitis or asymptomatic sacroiliitis. The treatment of these rheumatologic disorders is based on the application of general measures and the use of nonsteroidal anti-inflammatory agents; intraarticular corticosteroid administration may eventually become necessary. Sulphasalazine and/or infliximab, which are indicated when the previously mentioned measures fail, can be used to treat both the articular and intestinal diseases simultaneously.
Comment in
-
[Enteropathic arthritis].Gastroenterol Hepatol. 2006 Jan;29(1):62. doi: 10.1157/13083253. Gastroenterol Hepatol. 2006. PMID: 16393635 Spanish. No abstract available.
Similar articles
-
Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease.World J Gastroenterol. 2009 May 28;15(20):2449-55. doi: 10.3748/wjg.15.2449. World J Gastroenterol. 2009. PMID: 19468993 Free PMC article. Review.
-
Current issues in pediatric inflammatory bowel disease-associated arthropathies.World J Gastroenterol. 2014 Jan 7;20(1):45-52. doi: 10.3748/wjg.v20.i1.45. World J Gastroenterol. 2014. PMID: 24415857 Free PMC article. Review.
-
[The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].Acta Med Croatica. 2013 Apr;67(2):195-201. Acta Med Croatica. 2013. PMID: 24471303 Review. Croatian.
-
The joint-gut axis in inflammatory bowel diseases.J Crohns Colitis. 2010 Sep;4(3):257-68. doi: 10.1016/j.crohns.2009.11.005. Epub 2009 Nov 30. J Crohns Colitis. 2010. PMID: 21122514 Review.
-
Review article: joint involvement in inflammatory bowel disease.Aliment Pharmacol Ther. 2004 Oct;20 Suppl 4:36-42. doi: 10.1111/j.1365-2036.2004.02044.x. Aliment Pharmacol Ther. 2004. PMID: 15352892 Review.
Cited by
-
Incidence and Course of Joint Inflammation Associated with Inflammatory Bowel Disease in Patients Undergoing Treatment with Vedolizumab/Ustekinumab: The VEDUSTAR Study.J Clin Med. 2024 Feb 14;13(4):1076. doi: 10.3390/jcm13041076. J Clin Med. 2024. PMID: 38398390 Free PMC article.
-
Associations of MICA Polymorphisms with Inflammatory Rheumatic Diseases.Open Rheumatol J. 2015 Nov 24;9:94-100. doi: 10.2174/1874312901409010094. eCollection 2015. Open Rheumatol J. 2015. PMID: 26862354 Free PMC article.
-
Rheumatic manifestations of inflammatory bowel disease.World J Gastroenterol. 2009 Nov 28;15(44):5517-24. doi: 10.3748/wjg.15.5517. World J Gastroenterol. 2009. PMID: 19938189 Free PMC article. Review.
-
Analysis of immunologic comorbidities in ulcerative colitis patients: a tool to prevent exacerbations in ulcerative colitis cases.Nagoya J Med Sci. 2022 Nov;84(4):733-745. doi: 10.18999/nagjms.84.4.733. Nagoya J Med Sci. 2022. PMID: 36544593 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials